On January 5, 2022 Adlai Nortye Ltd. ("Adlai Nortye"), a clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies, reported that the first patient was dosed in the Phase I clinical trial in the U.S. to evaluate the safety, tolerability, PK and preliminary efficacy of the orally available, small-molecule PD-L1 inhibitor AN4005 in patients with advanced tumors (Press release, Adlai Nortye Biopharma, JAN 5, 2022, View Source [SID1234598290]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Adlai Nortye aspires to develop differentiated cancer immunotherapy medicines for global markets. The Company’s "cocktail" therapy strategy represents the third wave of immuno-oncology therapy, featuring the combination of an immune checkpoint inhibitor with two or more additional cancer therapies. The Company expects it to achieve synergistic and calibrated anti-cancer effects with a significant higher overall response rates than present combination therapies. As a potential first-in-class, orally available, small-molecule PD-L1 inhibitor, AN4005 has exhibited excellent in vitro and in vivo activities, favorable safety profile, as well as the ability to promote adaptive immune response for antitumor efficacy in preclinical studies, and the Company believes that it has the potential to serve as a backbone drug in the emerging next wave of cocktail immuno-oncology therapies, opening a new avenue for tumor immunotherapy based on the PD-1/PD-L1 signaling pathway," said Dr. Lars Birgerson, Chief Medical Officer of Adlai Nortye, and Chief Executive Officer of Adlai Nortye USA.

About AN4005

AN4005 is an orally available, small-molecule PD-L1 inhibitor that demonstrates antitumor activity by the blockade of PD-1/PD-L1 interaction. In nonclinical studies, AN4005 has demonstrated significant pharmacological activity, target engagement and acceptable safety profiles, which support the clinical development as a potential therapy for advanced malignancies. In pharmacology studies, AN4005 was shown to functionally overcome the inhibition derived from PD-1/L1 interaction in reporter- and human PBMC (hPBMC)-based cellular assays. Small molecule PD-(L)1 inhibitors are expected to provide several benefits over mAbs, such as, allowing for oral administration, lower production costs, improved tumor penetration, and lack of immunogenicity.

On January 5, 2022 Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, reported that Helen Sabzevari, PhD, President and CEO of Precigen, will present a corporate and clinical overview at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 3:45 PM ET (Press release, Precigen, JAN 5, 2022, View Source [SID1234598289]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Sabzevari will also participate in a panel discussion titled, The Emerging Cell & Gene Therapy Landscape – From Hope to Reality, which will be hosted by Scott Gottlieb, MD, at the H.C. Wainwright BioConnect 2022 Conference on January 11, 2022 at 12:00 PM ET.

Participants may access the live webcasts of the virtual events through Precigen’s website in the Events & Presentations section at investors.precigen.com/events-presentations.

On January 5, 2022 Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, reported its participation in and presentation at the 40th Annual J.P. Morgan Healthcare Conference (Press release, Ascentage Pharma, JAN 5, 2022, View Source [SID1234598288]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Dajun Yang, Chairman & CEO of Ascentage Pharma, will present at the conference on January 10th, 2022 at 9:00-9:25 AM ET (10:00-10:25 PM China Standard Time).

The annual J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry. The 40th Conference will take place virtually from January 10th through January 13th, 2022, ET.

The webcast of the presentation can be listened at the link below.

View Source;kiosk=true

On January 5, 2022 NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), reported that the evaluation of NOX-A12 by a leading international pharmaceutical company in a non-oncology indication announced on June 24, 2019 has been completed (Press release, NOXXON, JAN 5, 2022, View Source [SID1234598287]). The pharmaceutical company has decided not to pursue further work with NOX-A12 in this field and to terminate the collaboration agreement. The indication will remain undisclosed.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"While this decision comes as a disappointment to us and our shareholders, the significant investment in time and resources of the pharmaceutical partner over the last two years to evaluate NOX-A12 in a non-oncology indication indicates the unique potential of NOX-A12’s direct chemokine-targeting action versus competing single receptor agents that do not fully block CXCL12-receptor interactions. While the biological hypothesis tested by the pharmaceutical partner did not work in the evaluated indication, we are pleased that the pharma research and development team worked so diligently on testing this additional therapeutic potential of NOX-A12. We remain committed to the development of NOX-A12 in oncology indications and look forward to updating the market on clinical progress we make in brain and pancreatic cancers," said Aram Mangasarian, CEO of NOXXON.

NOX-A12 is currently under clinical development in two indications:

Glioblastoma (GBM) – a Phase 1/2 study of NOX-A12 + radiotherapy (GLORIA) in patients newly diagnosed with aggressive brain cancer is ongoing. All patients have been recruited in all three dose cohorts (200, 400 or 600 mg NOX-A12 per week), and will have completed 6 months of therapy in Q1 2022. Based on the encouraging data obtained from the two initial dose cohorts, expansion arms of the study have been initiated to assess potential synergistic benefit of NOX-A12 with additional treatment combinations. As a next step, a pivotal trial is planned to start in 2022.
Pancreatic cancer – following the promising results from the OPERA trial, a Phase 2 study (OPTIMUS) comparing two NOX-A12 combinations with anti-PD-1 antibody and two different standard of care chemotherapy regimens in second-line patients is expected to start in 2022. For this trial, NOXXON and MSD (Merck & Co., Inc., Kenilworth, N.J. USA) have entered into their second collaboration.

On January 5, 2022 Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, reported that Janux management will participate in a fireside chat at the virtual H.C. Wainwright BioConnect Conference being held January 10 to 13 (Press release, Janux Therapeutics, JAN 5, 2022, View Source [SID1234598286]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The fireside chat will be available for on-demand viewing beginning January 10, at 7:00 a.m. ET via the Investors & Media section of Janux’s website. An archived replay of the webcast will be available on the website for approximately 90 days following the presentation.